Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
Above averageRegeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for people with serious diseases. Our products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.
In the company’s own words · 10-K filed Feb 4, 2026 · SEC EDGAR
Business segments
Q2 2026 · $4.05BThe company’s own SEC segment disclosure.
- Share Of Profit Losses$2.03B50%
- EYLEAHD$596.3M15%
- Eylea Net Product Sales$412.2M10%
- LIBTAYO Net Product Sales$342.6M8%
- Product And Service Other$193.3M5%
- Reimbursement Of Commercialization Related Expenses$188.8M5%
- Other (4)$286.2M7%
Regeneron Pharmaceuticals (REGN) reported revenue of $4.29B in Q2 2026 (quarter ended Jun 30, 2026), up 17% from the same quarter a year earlier. That came with net income of $1.30B (30% of revenue). For the full year FY2025, revenue was $14.3B (+1.0% year on year) and net income $4.50B. Its largest product in Q2 2026 was Share Of Profit Losses at $2.03B, 50% of the disclosed total, well ahead of EYLEAHD at 15%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Biotechnology
The closest names by size in the same industry